Strategic Developments in 3D Bioprinting Market: What’s New?

3D Bioprinting Market - Inkwood Research

3D bioprinting largely focuses on the fabrication of anatomical replicas. It offers significant accuracy in the spatial placement of biomaterials, drugs, DNA, proteins, and cells to better guide tissue formation and generation. According to Inkwood Research, the global 3D bioprinting market is expected to project a CAGR of 16.69% during 2023-2032 and garner a revenue of $5693.82 million by 2032.

This blog focuses on the new strategic developments in the 3D bioprinting market.

  • Amgen’s Accelerated Drug Testing using a Human Tonsil

Researchers at Amgen British Columbia are using a human tonsil obtained from tonsillectomies to produce a complex cell culture platform to mimic the immune system outside the body. Tonsil tissue encompasses a rich source of immune cells. These include B cells that create antibodies and helper T cells that nudge B cells to make targeted antibodies.

Upon being provided the materials to culture the tonsil tissue, the cells formed 3D clusters spontaneously. These behave similarly to that in the body. The researchers plan to use these cultures to test medicines to better understand a drug’s ability to elicit an immune response.

According to Chadwick King, executive director of Research and site head of Amgen British Columbia, “In this case we are using three-dimensional organoid-like structures that allow us to better replicate human immunity. The long-term goal is to learn from this biology so we can better predict immunity using Artificial Intelligence (AI) and Machine Learning (ML) in the future.” (Source)

Predicting which protein-based medicines evoke an immune response that can neutralize the molecule remains a big pain point in drug development. Accordingly, the immune tissue platforms may assist in producing new antibodies for development.

  • BioArm joins Cancer Research

Researchers at the University of Cambridge and King’s College London developed BioArm, a low-cost extrusion-based bioprinter. It can be easily transported, folded, and reassembled for printing. It can manufacture complex tumoroids (around 90 seconds per tumoroid) to test potential immunotherapy treatments. Tumoroids are 3D cell cultures that mimic tumor tissues.

Immunotherapy uses the immune system to identify and fight cancer cells. There have been increased efforts to mimic the tumor microenvironment with regard to in vitro cancer models for therapeutic testing. Also, modeling a tumor in vitro can help minimize the animal model used for treatment methods in cancer research.

In this regard, 3D bioprinting is an efficient tool to help construct in vitro cancer models. However, the existing bioprinters are difficult to maneuver or reassemble. In comparison, BioArm is portable and can be assembled and disassembled within 15 minutes.

Corrado Mazzaglia, Research Associate in the Biointerface Research Group, says, “Bioprinted cancer models mimic the 3D heterogeneity of real tumors. BioArm has the potential to screen a wide range of tumor therapies and could play a crucial role in the future development of cancer drug testing approaches.” (Source)

  • CollPlant and Stratsys merge Technologies for Industrial-Scale Bioprinting of Organs and Tissues

On 4th April 2023, Stratasys and CollPlant announced a joint development & commercialization agreement to develop a solution to bio-fabricate human organs and tissues. This will be done using CollPlant’s collagen-based bioinks and Stratasys’ P3 technology-based bioprinter. It will further enable the production of CollPlant’s state-of-the-art breast implants designed to regenerate an individual’s natural breast tissue without evoking an immune response. This is evaluated to facilitate a revolutionary alternative for reconstructive and aesthetic procedures.

Says Yehiel Tal, CEO of CollPlant, “We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer.”

  • Easy Gulping: DEGLUMED’s 3D Printed Personalized Medicine to Dysphagia Rescue

Dysphagia is a swallowing disorder. It affects 1 in 25 people in the United States. Dysphagia patients need more time and effort to move food from the mouth to the stomach. Also, it affects patients with neurodegenerative pathologies. For instance, over 50% of acute stroke patients in Europe are affected by post-stroke dysphagia (PSD).

DEGLUMED is a Spanish project funded by the Valencian Institute of Business Competitiveness (IVACE). The participants include Centrum Pharmaceutical Specialties, IT3D GROUP, NutriSpain, and AIMPLAS (Plastics Technology Centre). The project aims to provide solutions for people with swallowing problems.

The project integrates several technologies and methods to design drugs. These include hot melt extrusion, which facilitates complex formulations that can be used to obtain films. These films further disintegrate in the mouth. Additionally, a filament would be acquired to be used for Fused Deposition Modeling (FDM) 3D printing.

3D printing is evaluated to save energy and enable the bioavailability and reproducibility of the drug. Also, it offers advantages like the production & versatility of short series at affordable costs, savings in materials, personalization, the printing of complex structures integrating different materials, etc.

Toward Four-Dimensional (4D) Bioprinting?

In 4D bioprinting, the fourth dimension, ‘time,’ is incorporated with 3D bioprinting. The printed bioconstructs can change their functionalities or shapes either through external or internal stimuli. It is estimated to be a promising direction in the fabrication of living tissues in a shorter duration of in vitro culture. This does not require extensive casting in molds that prevent the integration of larger tissues with vascular networks or their fabrication.

One of our major findings with regard to the global 3D bioprinting market is the emergence of 4D bioprinting as a substitute for 3D bioprinting. It is assessed to be a disruptive innovation in tissue engineering since it facilitates the construction of functional & complex structures with stimuli-responsive materials.

By Akhil Nair


Which region projects immense growth potential in the global 3D bioprinting market?

Asia-Pacific projects immense growth potential in the global 3D bioprinting market.

What are the main growth restraints of the global 3D bioprinting market?

Operational challenges and the lack of skilled professionals are the global 3D bioprinting market.